Label-free electrochemical aptasensing of cardiac cell secretomes in cell culture media for the evaluation of drug-induced myocardial injury.
10.1016/j.jpha.2025.101234
- Author:
Zelin YANG
1
;
Xilin CHEN
1
;
Mingang LIAO
1
;
Feng LIAO
1
;
Wen CHEN
1
;
Qian SHAO
2
;
Bing LIU
1
;
Duanping SUN
1
Author Information
1. Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of Pharmaceutical Sciences, Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
2. Chongqing Engineering Research Center of Pharmaceutical Sciences, Chongqing Medical and Pharmaceutical College, Chongqing, 401331, China.
- Publication Type:Journal Article
- Keywords:
Antitumor drug evaluation;
Cardiac troponin I;
Electrochemical aptasensor;
Metal-organic framework
- From:
Journal of Pharmaceutical Analysis
2025;15(10):101234-101234
- CountryChina
- Language:English
-
Abstract:
Cardiac troponin I (cTnI), a widely used biomarker for assessing cardiovascular risk, can provide a window for the evaluation of drug-induced myocardial injury. Label-free biosensors are promising candidates for detecting cell secretomes, since they do not require labor-intensive processes. In this work, a label-free electrochemical aptasensor is developed for in situ monitoring of cardiac cell secretomes in cell culture media based on target-induced strand displacement. The aptasensing system contains an aptamer-functionalized signal nanoprobe facing trimetallic metal-organic framework nanosheets and a gold nanoparticle-based detection working electrode modified with DNA nanotetrahedron-based complementary DNA for indirect target detection. The signal nanoprobes (termed CAHA) consisted of copper-based metal-organic frameworks, AuPt nanoparticles, horseradish peroxidase, and an aptamer. When the aptasensor is exposed to cardiac cell secretomes, cTnI competitively binds to the aptamer, resulting in the release of signal nanoprobes from the biorecognition interface and electrochemical signal changes. The aptasensor exhibited rapid response times, a low detection limit of 0.31 pg/mL, and a wide linear range of 0.001-100 ng/mL. We successfully used this aptasensor to measure cTnI concentrations among secreted cardiac markers during antitumor drug treatment. In general, aptasensors can be used to monitor a variety of cardiac biomarkers in the evaluation of cardiotoxicity.
